Oral Lesions in Autoimmune Bullous Diseases:An Overview of Clinical Characteristics and Diagnostic Algorithm by Rashid, Hanan et al.
  
 University of Groningen
Oral Lesions in Autoimmune Bullous Diseases
Rashid, Hanan; Lamberts, Aniek; Diercks, Gilles F H; Pas, Hendri H; Meijer, Joost M; Bolling,
Maria C; Horváth, Barbara
Published in:
American journal of clinical dermatology
DOI:
10.1007/s40257-019-00461-7
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Rashid, H., Lamberts, A., Diercks, G. F. H., Pas, H. H., Meijer, J. M., Bolling, M. C., & Horváth, B. (2019).
Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic
Algorithm. American journal of clinical dermatology, 20(6), 847-861. https://doi.org/10.1007/s40257-019-
00461-7
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-02-2020
Vol.:(0123456789)
American Journal of Clinical Dermatology (2019) 20:847–861 
https://doi.org/10.1007/s40257-019-00461-7
REVIEW ARTICLE
Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical 
Characteristics and Diagnostic Algorithm
Hanan Rashid1 · Aniek Lamberts1 · Gilles F. H. Diercks1,2 · Hendri H. Pas1 · Joost M. Meijer1 · Maria C. Bolling1 · 
Barbara Horváth1
Published online: 16 July 2019 
© The Author(s) 2019
Abstract
Autoimmune bullous diseases are a group of chronic inflammatory disorders caused by autoantibodies targeted against 
structural proteins of the desmosomal and hemidesmosomal plaques in the skin and mucosa, leading to intra-epithelial or 
subepithelial blistering. The oral mucosa is frequently affected in these diseases, in particular, in mucous membrane pem-
phigoid, pemphigus vulgaris, and paraneoplastic pemphigus. The clinical symptoms are heterogeneous and may present with 
erythema, blisters, erosions, and ulcers localized anywhere on the oral mucosa, and lead to severe complaints for the patients 
including pain, dysphagia, and foetor. Therefore, a quick and proper diagnosis with adequate treatment is needed. Clinical 
presentations of autoimmune bullous diseases often overlap and diagnosis cannot be made based on clinical features alone. 
Immunodiagnostic tests are of great importance in differentiating between the different diseases. Direct immunofluorescence 
microscopy shows depositions of autoantibodies along the epithelial basement membrane zone in mucous membrane pem-
phigoid subtypes, or depositions on the epithelial cell surface in pemphigus variants. Additional immunoserological tests are 
useful to discriminate between the different subtypes of pemphigoid, and are essential to differentiate between pemphigus 
and paraneoplastic pemphigus. This review gives an overview of the clinical characteristics of oral lesions and the diagnostic 
procedures in autoimmune blistering diseases, and provides a diagnostic algorithm for daily practice.
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1 Department of Dermatology, University Medical Center 
Groningen, University of Groningen, Hanzeplein 1, 
9700 RB Groningen, The Netherlands
Key Points 
The clinical characteristics of oral lesions in autoimmune 
bullous diseases may overlap and diagnostic tests are 
required to differentiate.
Immunofluorescence microscopy is essential for dis-
criminating between autoimmune and non-autoimmune 
bullous diseases.
Direct immunofluorescence microscopy differentiates 
between pemphigus and pemphigoid diseases, and addi-
tional serological tests are required to diagnose paraneo-
plastic pemphigus.
1 Introduction
Autoimmune bullous diseases (AIBDs) are characterized 
by autoantibody-mediated blistering of the skin and/or 
mucous membranes [1]. These diseases can be subdivided 
into two groups based on the level of blistering; pemphigoid 
diseases characterized by subepithelial blistering and pem-
phigus diseases characterized by intra-epithelial blistering 
[2, 3]. Several AIBD subtypes exist within these two major 
groups, with distinct clinical and diagnostic features [4–6]. 
This review focusses on AIBD subtypes with involvement 
of the oral mucosa.
Mucous membrane pemphigoid (MMP) is a group of 
AIBDs that predominantly affects the mucous membranes, 
but may mildly involve the skin [2, 7]. Autoantibodies 
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are directed against structural proteins of the hemidesmo-
some in the epithelial basement membrane zone (EBMZ), 
or proteins that are closely related. Hemidesmosomal 
dysfunction leads to a loss of connection between basal 
epithelial cells and the dermis, resulting in subepithelial 
blistering. Mucous membrane pemphigoid includes dif-
ferent pemphigoid subtypes, such as anti-BP180 MMP 
(classic MMP) and anti-laminin-332 MMP. Epidermolysis 
bullosa acquisita (EBA) with predominant mucous mem-
brane involvement is also classified as a subtype of MMP. 
Linear IgA disease (LAD) is a subtype of pemphigoid and 
can present with predominant mucous membrane involve-
ment. Anti-p200 pemphigoid is an extremely rare disease 
and may also have mucosal involvement [8].
Pemphigus diseases comprise mucocutaneous intra-epi-
thelial blistering diseases that target desmosomal proteins, 
resulting in loss of cell adhesion between keratinocytes 
[3]. The two main variants are pemphigus vulgaris (PV) 
with autoantibodies targeting desmoglein 3 (DSG3) and 
sometimes desmoglein 1 (DSG1), and pemphigus folia-
ceus with autoantibodies reactive to DSG1 only. Pemphi-
gus vulgaris presents with mucosal lesions, and the skin 
may be involved, while in pemphigus foliaceus only the 
skin is affected. Other rare variants of pemphigus include 
pemphigus vegetans, pemphigus erythematosus, and fogo 
selvagem (endemic pemphigus foliaceus). The last two are 
clinical variants of pemphigus foliaceus with reactivity to 
DSG1 and present with only skin lesions. Paraneoplastic 
pemphigus (PNP) is a different disease entity related to 
malignancies, especially hematological malignancies and 
Castleman disease, and is often life threatening [1]. The 
clinical hallmark is painful oral mucosal lesions accompa-
nied with morphologically heterogenous skin lesions [9]. 
The pathomechanism of PNP is complex with involvement 
of both humoral and cellular autoimmunity.
Chronic oral lesions can be painful, and can seriously 
influence the quality of life, nutrition status, and den-
tal health of patients [10, 11]. Poor dental cleaning due 
to painful lesions may result in periodontitis, a chronic 
inflammatory disease of the gingiva [11]. If not managed 
adequately, patients are at risk of losing the surrounding 
teeth. Oral manifestations of MMP, PV, and PNP may 
seem identical; however, the health impact, treatment, 
and prognosis of the diseases differ substantially. There-
fore, it is important that clinicians make a quick and cor-
rect diagnosis. In addition to clinical assessment of the 
patient, immunodiagnostic tests are essential to differenti-
ate between the AIBD subtypes. The aim of this review 
is to provide clinicians with a complete overview of the 
clinical features of AIBDs predominantly involving the 
oral mucosa, and to describe the diagnostic process.
2  Mucous Membrane Pemphigoid
Mucous membrane pemphigoid is a group of chronic auto-
immune diseases characterized by subepithelial blister-
ing and affects mucosal surfaces of various sites. The oral 
mucosa is predominantly affected (85%), followed by the 
ocular (65%), nasal (20–40%), anogenital (20%), pharyngeal 
(20%), laryngeal (5–10%), and esophageal mucosa (5–15%) 
[2]. The skin may also be involved in 25–30% of the cases 
but in lesser extent than the mucous membranes [12]. Clini-
cal severity is highly variable in MMP [2].
2.1  Epidemiology and Etiology
Mucous membrane pemphigoid occurs predominantly in 
the elderly with a mean age of onset in the mid-60 s and an 
annual incidence of 1.3 and 2.0 newly diagnosed cases per 
million inhabitants in France and Germany [13–15]. Women 
are more often affected than men.
The etiology of MMP is unknown. A genetic associa-
tion in patients with MMP with HLA-DBQ1*0301 has been 
described, suggesting a role for T-lymphocyte recognition 
of antigens in the EBMZ [16–18]. The formation of subepi-
thelial blisters is caused by IgG and/or IgA autoantibodies 
directed against several components of the hemidesmosome, 
in particular BP180 and BP230 [12, 19]. In two thirds of 
the MMP cases, autoantibodies are directed against BP180, 
mainly against the C-terminal domain and/or the NC16A 
domain, whereas in bullous pemphigoid, autoantibodies 
are primarily directed against the NC16A domain [20–23]. 
Different epitope profiles of BP180 may be associated with 
the presence of mucosal involvement with or without skin 
lesions. Other antigens in MMP include laminin 332, p200, 
type VII collagen, and α6ß4 integrin. In MMP, the presence 
of both IgG and IgA in serum is associated with the need for 
long-term systemic treatment [24].
2.2  Clinical Features
Oral lesions are usually the initial manifestation in MMP 
and may present anywhere on the oral mucosa (Fig. 1a–c) 
[25, 26]. The gingiva is most often affected in MMP and 
may represent the onset of the disease [14, 15, 27–29]. Des-
quamation of the gingiva appears as patches or widespread 
erythema [26]. Patients with oral MMP present with tense 
serous or hemorrhagic bullae that easily rupture as a result of 
mechanical forces, leading to irregularly shaped erosions or 
ulcers with yellowish slough surrounded by an erythematous 
halo [19, 26]. Symptoms may consist of pain, dysphagia, 
soreness, foetor, bleeding and/or peeling of the mucosa [30, 
31]. Other commonly affected areas are the palatal mucosa 
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and less often the buccal mucosa and the tongue [27]. Oral 
lesions often heal without scarring unlike other subtypes of 
MMP such as ocular MMP [19]. Anti-laminin 332 MMP 
is a rare subtype often leading to cicatrization and tissue 
destruction, with possible involvement of pharyngeal and 
laryngeal mucosa, and a risk of airway obstruction [32]. 
There are conflicting reports about an increased relative risk 
for malignancy in this subtype [33, 34]. In some cases, the 
clinical presentation of oral MMP may resemble that of oral 
lichen planus [35, 36].
2.3  Other Pemphigoids with Oral Involvement
Other pemphigoid subtypes may also present with oral 
lesions; however, the difference between MMP and cuta-
neous pemphigoids relies on the predominant affected site. 
Bullous pemphigoid primarily affects the skin, with occa-
sionally mild mucosal lesions, whereas MMP predominantly 
affects the mucous membranes [7]. Epidermolysis bullosa 
acquisita and LAD are pemphigoid subtypes that also can 
have predominant mucosal involvement; however, they are 
not restricted to the oral mucosa alone.
Epidermolysis bullosa acquisita is a subtype of pemphig-
oid characterized by tissue-bound and circulating autoanti-
bodies against type VII collagen, the main component of the 
anchoring fibrils below the lamina densa [2]. The incidence 
ranges from 0.25 and 0.5 new cases per million per year 
in central Europe and the disease may develop at any age 
[13]. Two major forms of EBA can be distinguished: the 
non-inflammatory variant (also termed classical or mecha-
nobullous EBA) and the inflammatory variant [2, 37]. The 
first form presents with fragile skin, nail loss, and tense 
Mucous membrane 
pemphigoid
Pemphigus vulgaris
Paraneoplastic 
pemphigus
Stevens-Johnson 
syndrome
Oral lichen planus
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Fig. 1  Overlapping features in autoimmune bullous diseases, Ste-
vens–Johnson syndrome, and oral lichen planus demonstrate that oral 
blistering diseases cannot be differentiated based on clinical presenta-
tion. Lesions include desquamative gingivitis (a, d, m), cheilitis (e, f, 
g, h, j, k), erythema and erosions and blistering of the buccal mucosa 
(b, i, l, n), palatum (c), and tongue (e, o)
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vesiculobullous eruptions on trauma-prone areas followed 
by scarring, milia, and hypo- or hyperpigmentation. These 
manifestations are also seen in the genetic skin blistering 
disorder, dystrophic epidermolysis bullosa with a mutation 
in the same protein, type VII collagen. The inflammatory 
variant resembles bullous pemphigoid, and blisters heal 
without scarring. Involvement of mucous membranes is 
present in more than half of the cases in both variants [38]. 
The oral mucosa may show erosions, bullae, gingivitis, loss 
of teeth, and reduced ability to open the mouth. Oral lesions 
heal with scar formation, and are often therapy resistant [29, 
39].
Linear IgA disease is a rare disease characterized by lin-
ear deposition of solely IgA along the EBMZ. The incidence 
ranges between 0.23 and 0.57 per million per year in Europe 
[40]. Both children and adults can be affected, in particular, 
before the age of 5 years and after the age of 60 years [41]. 
Linear IgA disease in childhood seems to be self-limiting, 
whereas the adult type is characterized by a more chronic 
disease course. Patients with LAD present with bullae on 
urticarial plaques in a ring-shaped distribution, also called 
the ‘crown of jewels’, on the trunk and extremities. Involve-
ment of mucous membranes is seen in 80% of the cases 
[41]. Oral involvement may consist of painful erosions and 
ulceration, and in some cases, erosive cheilitis or desqua-
mative gingivitis [42]. Other affected areas in LAD include 
ocular, nasal, and genital mucous membranes [41]. The IgA 
autoantibodies in LAD are mainly directed against BP180 
and its ectodomain cleavage products, the 120-kDa (LAD-1) 
and the 97-kDa (LABD97) antigen [2].
Anti-p200 pemphigoid was first described in 1996 and is 
caused by autoantibodies against a 200-kDa (p200) protein 
of unknown identity located in the lamina lucida [43, 44]. 
The clinical presentation is heterogeneous and consists of 
itchy tense bullae and erythematous or urticarial plaques, 
which are mainly present on the hands, feet, extremities, and 
trunk [45]. Oral and genital mucous membranes are involved 
in 50% of the cases [8].
3  Pemphigus Vulgaris
3.1  Epidemiology
Pemphigus vulgaris is a rare disease with an estimated prev-
alence of 94.8 per million inhabitants in Germany in 2014 
[46]. The estimated annual incidence in European countries 
lies within the range of 0.7–8 cases per million inhabitants, 
and is the highest among patients living in South-Eastern 
European countries [47–55]. On average, patients develop 
PV in the fifth decade of life, with a slight female pre-
dominance [46, 54, 55]. The observed mortality rates are 
increased 2.3- to 3.3-fold compared with the general popula-
tion, with 1-, 5-, and 10-year survival rates of 95%, 93%, and 
90%, respectively [55–59]. Infections are the most frequent 
cause of death, particularly pneumonia and sepsis [56, 57].
3.2  Pathogenesis
The pathogenesis of PV relies on IgG-targeting desmosomal 
proteins DSG1 and DSG3 [60].
Genetics seems to contribute in the disease pathogenesis, 
as population-specific associations between PV and several 
HLA class II genes have been described, and also associa-
tions with non-HLA genes were reported [61, 62]. Overall, 
the most commonly reported PV-associated HLA class II 
alleles are HLA-DQB1*0503 and DRB1*0402, which are 
expressed on antigen-presenting cells.
Most patients with PV with only DSG3 autoantibodies 
develop a mucosal-dominant phenotype, whereas patients 
with both DSG1 and DSG3 reactivity display mucocuta-
neous lesions [63]. This is explained by the desmoglein 
compensation hypothesis [63, 64]. In the skin, DSG3 is 
only expressed at the basal layers, while DSG1 is expressed 
throughout the whole epithelium, and therefore can com-
pensate for DSG3 function loss. However, in the mucosa, 
DSG3 is expressed in the whole epithelium, whereas DSG1 
expression is high in the superficial layers, and significantly 
lower in the basal layers and therefore loss of DSG3 cannot 
be adequately compensated by DSG1. This explains why 
patients with exclusive DSG3 reactivity display mucosal 
lesions only. Interestingly, seroconversion from DSG3 to 
DSG1 reactivity and vice versa may occur during the dis-
ease course, with corresponding conversion of the clinical 
pemphigus phenotype.
Several theories concerning the blistering mechanism in 
PV exist. One theory suggests the binding of autoantibod-
ies may interfere with the cell adhesion ability of desmo-
gleins by steric hindrance [65, 66]. Others observed that 
autoantibodies induce clustering of the desmogleins, lead-
ing to non-assembly of the desmosomes and depletion of 
desmogleins by internalization, which can weaken the des-
mosomes’ adhesion strength [67–69]. Last, there is evidence 
that signaling pathways play a role in acantholysis in PV 
[70, 71]. Some authors hypothesize that signaling pathways 
in PV may lead to alteration of the cytoskeleton, leading 
to shrinkage of the basal keratinocytes, and eventually to 
programmed cell death [72, 73]. Animal studies and in vitro 
experiments have shown that the IgG Fab fragments purified 
from the sera of patients with PV directly lead to a pemphi-
gus disease phenotype, implying that Fc-mediated effects 
of IgG are not necessarily involved in the pathogenesis [74, 
75].
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3.3  Clinical Features
Patients with PV often present with oral mucosal involve-
ment, with or without skin lesions (Fig. 1d–f). The oral 
mucosa is the first site to be involved in 50–80% of patients 
with PV [25]. Mucocutaneous PV is more common than 
mucosal dominant PV [76]. Oral involvement in pemphigus 
vegetans, a clinical variant of PV, is reported in 60–80% 
of the cases [77]. Skin lesions typically consist of flaccid 
blisters that easily rupture, leaving erosions and crusts, 
and are commonly distributed on the face, scalp, and upper 
chest [3]. The oral mucosa displays erosions more often 
than intact blistering. The palatal mucosa, buccal mucosa, 
labial mucosa, and the tongue are most commonly affected. 
Desquamative gingivitis is seen in approximately one fourth 
of patients with PV, whereas it is the most common (and 
often the sole) manifestation in patients with MMP [28, 
76]. Mucous membranes other than the oral mucosa may be 
involved, including the pharyngeal and nasal mucosa, and 
less common, the genital, ocular, laryngeal, and esophageal 
mucosa. Oral lesions heal without scarring.
4  Paraneoplastic Pemphigus
4.1  Epidemiology
Paraneoplastic pemphigus, first described by Anhalt et al., is 
a distinct, extremely rare, and often lethal variant of pemphi-
gus associated with malignancy [78]. In most cases, underly-
ing B-cell lymphoproliferative diseases can be found, such 
as non-Hodgkin lymphomas, chronic lymphatic leukemia, 
or Castleman disease. Paraneoplastic pemphigus is rarely 
associated with other solid tumors [79]. However, 10% of 
cases have no malignancy at the time of the diagnosis and 
data on follow-up are lacking [80].
The diagnosis of PNP is based on three criteria: (1) initial 
mucosal involvement; (2) detection of circulating autoanti-
bodies against envoplakin, periplakin, and/or a2-macroglob-
ulin-like 1 (A2ML1); and (3) the detection of an underlying 
neoplasm [9]. Paraneoplastic pemphigus may occur at any 
age without sex predominance, although most of the cases 
are diagnosed at approximately 60 years of age [80, 81]. The 
disease may also develop in children, frequently associated 
with Castleman disease [9].
The underlying malignancies in PNP can be difficult 
to control, which makes the prognosis very poor with a 
reported mortality rate of 75–90% [82, 83]. The survival rate 
in a French cohort after 1, 2, and 5 years was 49%, 41%, and 
38%, respectively [84]. The main causes of death include 
infections, the progression of the neoplasm, and bronchioli-
tis obliterans [80, 84, 85].
4.2  Pathogenesis
The pathogenesis of PNP is complex, with involvement of 
both the humoral and cellular immune systems [79]. Some 
data confirm the presence of certain genetic predispositions 
in PNP. A Chinese and a French cohort show a clear associa-
tion between PNP and HLA-Cw*14, HLA-DRB1*04, and 
HLA-DRB1*14 [86, 87]. Currently, different mechanisms 
are assumed to contribute to the development of PNP [9]. 
Direct effects of the associated tumor were found, such as 
production of autoantibodies targeting epithelial antigens, 
and high interleukin-6 secretion, resulting in reactive auto-
immunity [82, 88]. Indirectly, autoreactive cellular cytotox-
icity against the underlying tumor has been described, show-
ing natural killer cells, macrophages, and cytotoxic CD8 + T 
lymphocytes, the latter producing high levels of interferon-γ 
and tumor necrosis factor-α in PNP skin [89]. The cellular 
response may result in an interface dermatitis revealing new 
antigens (epitope spreading). Moreover, a humoral immune 
response against the tumor may lead to cross-reactivity with 
epithelial antigens, also called antigen mimicry [82, 90, 91].
A heterogeneous autoantibody repertoire can be found 
in PNP; envoplakin, periplakin, BP230, desmoplakin, and 
plectin are all plakin family proteins that may be targeted. 
Recently, epiplakin was described as an autoantigen in PNP 
associated with bronchiolitis obliterans in Japanese patients 
[92]. Autoantibodies against several desmosomal cadherins 
such as DSG1 and DSG3, and desmocollin-1, -2, and -3 
have also been identified [93]. The latest discovered protein 
targeted by PNP autoantibodies is the A2ML1 protein, an 
epithelial-expressed protease inhibitor [94]. In some cases, 
autoantibodies against the desmosomal armadillo protein 
plakophilin-3, BP180, laminin 332, and the neuromuscu-
lar junction were detected [95, 96]. Although PNP and PV 
share some cadherin autoantigens, the targeted epitopes and 
the IgG isotypes differ in the two diseases [97]. The exact 
pathogenic role of autoantibodies targeting different antigens 
and their influence on the disease phenotype are uncertain.
4.3  Clinical Features
The most pronounced clinical sign is involvement of the 
mucosa, predominantly the oral mucosa with painful stoma-
titis, gingivitis, hemorrhagic cheilitis, erythema, blistering, 
and erosions (Fig. 1g–i) [80, 98]. The involvement of the 
mucosa may extend to the upper gastrointestinal tract and 
upper airways. The conjunctiva is involved in 70% of the 
cases, with the presence of corneal ulceration, perforation, 
melting, or symblepharon [99].
Moreover, PNP shows a wide spectrum of cutaneous 
eruptions such as macules, papules, plaques, and blister-
ing erosions. Five clinical phenotypes of PNP can be dis-
tinguished; PV-like, bullous pemphigoid-like, erythema 
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exsudativum multiforme-like, graft vs. host disease-like, 
and lichen planus-like [9, 100, 101].
In addition, PNP can affect other organs and tissues 
besides the mucosa and skin, suggesting the use of the name 
paraneoplastic autoimmune multi-organ syndrome according 
to the latest literature [79]. Yet, no international consensus 
exists on the use of the term paraneoplastic autoimmune 
multi-organ syndrome. Pulmonary involvement in the form 
of bronchiolitis obliterans occurs in 30% of the PNP cases, 
which is fatal in 90% of the cases [85]. Bronchiolitis oblit-
erans is very common in Castleman disease-associated PNP 
(71%) and a DSG3-dependent mechanism is assumed [80, 
85, 102]. Other affected organs besides the lungs include 
the thyroid gland, kidneys, and smooth muscle tissue [9]. 
Muscle weakness (39%) and myasthenia gravis can also be 
seen in PNP and are associated with a certain antibody rep-
ertoire [96].
5  Diagnostic Algorithm in Patients with Oral 
Blisters
The diagnostic algorithm in patients with oral blisters 
includes the performance of two biopsies for histopathol-
ogy and direct immunofluorescence microscopy (DIF), col-
lecting a serum sample for immunoserological tests, and 
the performance of microbiological diagnostics to test for 
infectious causes (Fig. 2).
5.1  Main Differential Diagnosis
The differential diagnosis of erosive oral lesions include 
infectious agents, due to viruses and bacteria, drug-induced 
reactions, inflammatory conditions, and systemic diseases 
(Table 1). These conditions have some specific morphologi-
cal features and overlapping clinical features, therefore his-
tology is required for the diagnosis.
Oral lesions caused by infectious agents are usually tran-
sient. Primary infection with herpes simplex is the most 
common viral cause of erosions and blisters in the oral 
mucosa [103]. Stevens–Johnson syndrome and toxic epi-
dermal necrolysis are severe, mostly drug-induced reactions 
with an abrupt onset of erosive stomatitis and hemorrhagic 
cheilitis followed by widespread skin lesions (Fig. 1j–l) 
[104]. The gingiva is rarely affected in Stevens–Johnson 
syndrome and toxic epidermal necrolysis. Other mucosal 
involvement is frequently seen, such as ocular and genital 
involvement.
Recurrent aphthous stomatitis is the most frequent inflam-
matory condition of the oral mucosa with recurrent self-
limiting ulcers affecting non keratinized mucosa. Multiple 
factors are involved in the etiology of recurrent aphthous 
stomatitis [103]. Behçet syndrome is a chronic multi-system 
condition characterized by diffuse aphthous erosions and 
ulcers on the labial, buccal, and lateral tongue mucosa [31]. 
Ocular and genital involvement is also frequently seen.
Lupus erythematosus is a systemic autoimmune disorder 
with a wide variety of clinical features. Oral lesions in lupus 
erythematosus are usually multiple, located on the buccal 
mucosa, hard palate, lips, and gingiva. The distribution is 
asymmetrical with different morphological features ranging 
from plaques, erythema, and ulcerations [19].
Oral lichen planus is a chronic immune mediated dis-
ease with highly variable clinical features ranging from 
subtle white reticular patterns to erosions and ulcerations 
(Fig. 1m–o). Lesions are usually symmetrically distributed 
in the oral cavity. Affected sites of the oral cavity include the 
buccal mucosa, tongue, and gingiva. Histopathologic biop-
sies of oral lichen planus often show sub-epithelial blister-
ing without preservation of the basal cells, in contrast to 
pemphigoid [19].
5.2  Nikolsky Sign
When encountering a patient with a blistering disease, cli-
nicians may test the positivity of the Nikolsky sign consist-
ing of two variants. The Nikolsky sign I (or direct Nikolsky 
sign) can be tested by sideward friction of healthy-looking 
skin or mucosa, and is positive when the mechanical pres-
sure induces an erosion. The Nikolsky sign II (or indirect 
Nikolsky sign) tests the ability to split the epidermis by 
pulling the blister remnant, and is positive when the blister 
extends far beyond the existing erosion [105, 106].
In patients with a clinical phenotype compatible with 
AIBD, the Nikolsky sign on the skin may be a useful diag-
nostic tool with moderate sensitivity; however, a very high 
specificity for the diagnosis of pemphigus diseases [107]. 
The Nikolsky sign can also be tested on the gingiva in 
patients with only oral involvement, however, it is often 
positive in both MMP and pemphigus, and therefore not 
a useful tool to differentiate between these diseases [108]. 
Moreover, the Nikolsky sign on the oral mucosa may cause 
unnecessary injury to the tissue and pain to the patient.
5.3  Histopathological Findings
Histopathology alone is not sufficient to diagnose AIBD 
because it often is non-specific, but is useful to differentiate 
between non-autoimmune bullous diseases in the differen-
tial diagnosis (Table 1). A skin biopsy for histopathologi-
cal examination should be taken at the edge of the blister, 
including one third blister and two thirds perilesional skin 
[4, 6]. Mucosal biopsies for histopathology are usually taken 
from lesional mucosa. In the presence of a blister, a biopsy 
for histopathology should be taken at the edge of the blister 
to determine the level of the blister in AIBD. In the presence 
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of an ulceration, a biopsy for histopathology should be taken 
from the perilesional erythema. One of the differential diag-
noses of an ulcerative process is oral lichen planus. In this 
respect, the presence of an interface dermatitis can only be 
determined in lesional tissue. Moreover, another differential 
diagnosis is spinocellular carcinoma and this also can only 
be excluded with a lesional biopsy.
In MMP, histopathological features may include subepi-
thelial blistering with an infiltrate consisting of eosinophils, 
lymphocytes, and/or neutrophils [25]. In EBA, histopatho-
logical findings are dependent on the disease phase, as in 
early stages, vacuolar changes along the BMZ accompanied 
with edema in the papillary dermis are shown. In a later 
stage, a subepithelial blister is formed with a mixed infil-
trate consisting of neutrophils, eosinophils, and mononuclear 
cells [37]. In LAD, an anti-p200 pemphigoid histopatho-
logical examination of lesional skin may show subepithelial 
blister formation with mainly neutrophilic infiltrate in the 
papillary dermis, in anti-p200 pemphigoid, eosinophils are 
sometimes present [109, 110].
Characteristic histopathological findings of PV are acan-
tholysis with rounding up of keratinocytes, and a suprabasi-
lar cleft [111]. The basal keratinocytes remain attached to 
the basement membrane, and line the blister floor, resulting 
in a typical tombstone appearance. Eosinophils may be 
present, infiltrating the epidermis [6]. The histopathology 
of PNP is not exclusive and different patterns can be seen, 
with vacuolar interface dermatitis or keratinocyte necrosis 
in most cases, and rarely intra-epithelial acantholysis [112].
5.4  Direct Immunofluorescence Microscopy
Direct immunofluorescence plays a very important role in 
differentiating between the different AIBDs. Autoantibodies 
bound in the skin are visualized by adding a fluorescent-
labeled antibody against human IgG to a frozen skin sec-
tion [113]. Skin biopsies should measure 4 mm in diameter, 
and are preferably taken perilesional, 1–2 cm adjacent to a 
blister, to yield the highest sensitivity [114–116]. Mucous 
membrane biopsies should be at least 3 mm in diameter. 
Oral biopsies are recommended to be taken from the buccal 
mucosa, localized one third of the distance from the mouth 
corner to the last molar, to avoid the parotid duct [117]. A 
DIF biopsy of non-lesional buccal mucosa in patients with 
solely desquamative gingivitis is recommended [118]. A 
recent retrospective analysis showed comparable sensitiv-
ity of a DIF biopsy in normal and perilesional mucosa [119]. 
Biopsies for DIF should preferably be stored in 0.9% sodium 
chloride for 24 hours to reduce IgG background staining 
[120, 121]. For a transportation of several days, the biopsy 
can be stored in Michel’s medium.
The location of a DIF biopsy depends on the distribution 
of lesions. In patients with both skin and mucosal lesions, a 
skin biopsy is usually performed. In cases with only mucosal 
lesions, a mucosal biopsy is taken from the affected site. 
If the DIF result is negative, repeated biopsies, or biopsies 
from other mucosal sites or the skin can be taken [122, 123].
Direct immunofluorescence of intact perilesional mucosa 
in MMP shows deposition of IgG, in some cases, IgA 
autoantibodies and/or complement C3c along the EBMZ. 
The sensitivity of DIF microscopy for the diagnosis of MMP 
lies between 69 and 83%, and increases when multiple and 
repeated biopsies are performed [123–126]. Similar to 
MMP, EBA and anti-p200 pemphigoid show linear deposi-
tions of IgG and/or IgA and C3c along the EBMZ. In LAD, 
DIF is the reference standard for diagnosis, and is charac-
terized by a linear deposition of exclusively IgA along the 
EBMZ [116].
Analysis of the serration pattern by DIF discriminates 
between MMP subtypes, but can be indeterminable on 
mucosal biopsies, and performance of an additional skin 
biopsy may be considered [116, 127]. The classic MMP, 
anti-p200 pemphigoid, anti-laminin 332 pemphigoid, and 
LAD show a n-serrated pattern, due to binding of autoanti-
bodies against hemidesmosomal proteins above the lamina 
densa (Fig. 3a). Epidermolysis bullosa acquisita-type MMP 
can be diagnosed by recognition of an u-serrated pattern by 
Table 1  Differential diagnosis of oral blisters, ulcers, gingivitis, and 
stomatitis
SJS/TEN Stevens–Johnson syndrome/toxic epidermal necrolysis
Differential diagnosis
Autoimmune bullous diseases
Paraneoplastic pemphigus
Pemphigus vulgaris
Mucous membrane pemphigoid
Bullous pemphigoid
Linear IgA dermatosis
Epidermolysis bullosa acquisita
Anti-p200 pemphigoid
Drug-induced diseases
Methotrexate mucositis
SJS/TEN
Gingivostomatitis by checkpoint inhibitors
Systemic diseases
Oral lichen planus
Systemic lupus erythematosus
Graft vs. host disease
Epidermolysis bullosa
Behçet disease
Other
Causative infectious agents
Recurrent aphthous stomatitis
Angina bullosa haemorrhagica
Chronic ulcerative stomatitis
Contact dermatitis
Malignancy
Trauma
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binding of autoantibodies in the sublamina densa (Fig. 3b) 
[116, 120]. Exclusive linear IgA depositions with an u-ser-
rated pattern in patients with oral lesions without skin 
involvement is diagnosed as IgA MMP [128].
Direct immunofluorescence microscopy is the reference 
standard in pemphigus diagnosis, and shows binding of IgG 
on the epithelial cell surface (ECS) [114]. The deposition 
pattern might be smooth or granular, in line with the theory 
on clustering of desmogleins (Fig. 4a, b). Complement C3 
deposits may be found in approximately 61% of PV cases 
[28].
In PNP, the DIF on skin and mucosa may show deposi-
tion of IgG and C3c in an ECS pattern, in some cases with 
additional linear-granular depositions of mainly complement 
and sometimes IgG along the EBMZ (Fig. 5a) [129]. The 
combined ECS and anti-EBMZ pattern is seen in 27% of the 
cases; however, it has a very high specificity of 97%. Rarely, 
a linear anti-EMBZ pattern may be the only finding with DIF 
microscopy [130].
5.5  Immunoserology
Several immunoserologic tests are used to detect circulating 
autoantibodies against hemidesmosomal and desmosomal 
proteins, and may be valuable for diagnosing and discrimi-
nating between AIBDs. Circulating autoantibodies in serum 
of MMP are usually low in concentration and therefore not 
always detectable [27]. This is also the case in EBA, which 
lacks detectable circulating autoantibodies in more than half 
of the cases. In contrast, serological tests are essential for 
the diagnosis of PNP.
5.5.1  Indirect Immunofluorescence
With indirect immunofluorescence (IIF) microscopy, the 
patients’ serum is applied to a substrate, and after incuba-
tion and washing away unbound antibodies, a fluorescent-
labeled antibody visualizes autoantibodies bound to the 
substrate. Monkey esophagus is frequently used as a sub-
strate because it is widely commercially available. Indirect 
Fig. 3  Immunofluorescence results compatible with the diagnosis 
of pemphigoid diseases. a Direct immunofluorescence microscopy 
shows linear IgG along the epithelial basement membrane zone in 
an n-serrated pattern. b Direct immunofluorescence microscopy 
shows linear IgG along the epithelial basement membrane zone in a 
u-serrated pattern. c Indirect immunofluorescence microscopy on a 
substrate of salt-split skin (indirect immunofluorescence on salt-split 
skin), showing IgG bound to the epithelial side of the artificial split, 
wherein BP180 and BP230 are located. d Indirect immunofluores-
cence on salt-split skin showing IgG bound to the dermal side of the 
artificial split, wherein laminin-332, p200, and type VII collagen are 
located
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immunofluorescence on monkey esophagus shows the high-
est sensitivity for the diagnosis of pemphigus diseases, and 
circulating autoantibodies in a smooth ECS pattern can be 
identified in approximately 86–90% of patients with PV 
[114, 131].
A second commonly used substrate is salt-split skin 
(SSS), which can discriminate between pemphigoid sub-
types [8]. Salt-split skin is obtained by incubation of human 
skin in sodium for 2–3 days, resulting in a reproducible arti-
ficial split in the lamina lucida, with antigens located either 
at the epithelial or dermal side. Indirect immunofluores-
cence on SSS in classic MMP with autoantibodies directed 
against BP180 or BP230 shows binding to the epithelial side 
(Fig. 3c). Other subtypes of MMP show antibodies directed 
against p200, laminin-332, and type VII collagen, which 
bind to the dermal side of the artificial split (Fig. 3d). Anti-
laminin-332 MMP with epithelial binding has been reported. 
This is explained by the co-existence of antibodies to BP180 
or BP230 and the low sensitivity of the technique, which 
leads to a negative result of indirect immunofluorescence 
on the dermal side of the split skin [34]. In LAD, IIF on 
SSS exclusively shows IgA, which most often binds to the 
epithelial side, or the dermal side in the case of IgA-EBA-
type MMP [116].
Indirect immunofluorescence on a substrate of rat bladder 
is one of the few serological tests that can diagnose PNP, and 
therefore is highly important. Rat bladder is a perfect sub-
strate as it does not contain DSG1 and DSG3, but expresses 
desmoplakin, epiplakin, and periplakin [93]. Positive IIF on 
a rat bladder is very specific for PNP, and may show dif-
ferent patterns, such as urothelial cell surface staining and 
cytoplasmic staining (Fig. 5b) [130].
5.5.2  Other Immunoserological Tests
Enzyme-linked immunosorbent assay (ELISA) and immu-
noblot are commonly used to specify targeted antigens. 
The ELISA technique is performed using a 64-well plate, 
of which each well is coated with a specific AIBD-related 
antigen. Serum is added to enable autoantibodies to bind 
the specific antigen on the sides of the well. After washing 
away non-specific unbound antibodies, an enzyme-linked 
IgG conjugate is added. The enzyme substrate is applied in 
the next step, resulting in a measurable color reaction, of 
which the intensity reflects on the amount of autoantibodies. 
To perform the immunoblot technique, denatured proteins 
of the skin are first sorted based on molecular size by gel 
electrophoresis, and are transferred onto a membrane [132, 
133]. Autoantibodies directed against skin proteins can bind 
the membrane, and are visualized by staining. The molecu-
lar size of the stained protein identifies which antigen is 
targeted.
In MMP, the NC16A ELISA is frequently used for the 
detection of circulating autoantibodies; however, a retrospec-
tive study showed a high number of false-positives (11.3%) 
in non-pemphigoid controls [115]. Izumi et al. reported the 
detection of BP180 by full-length BP180 ELISA because 
MMP autoantibodies may target different regions, espe-
cially the C-terminal domain [134]. However, the full-length 
BP180 ELISA is not commercially available.
Enzyme-linked immunosorbent assay kits are also com-
mercially available for BP230 and type VII collagen [135]. 
The BP230 ELISA is less sensitive with an additional diag-
nostic added value of only 5% compared to NC16A ELISA 
in bullous pemphigoid [135]. The type VII collagen ELISA 
has a low sensitivity of 45%, and when combined with IIF 
on SSS the sensitivity rises to 50% [127]. The immunoblot 
assay in MMP has a highly variable sensitivity. Autoanti-
bodies targeting BP180, LABD97, LAD-1, and p200 can be 
detected by immunoblotting, although the latter requires a 
sophisticated preparation of a human dermal extract, which 
is only performed in highly specialized laboratories [45]. In 
LAD, immunoblot can detect circulating IgA autoantibodies 
against BP180, LABD97, or LAD-1.
Fig. 4  Direct immunofluorescence microscopy staining of a pemphi-
gus patient. a IgG staining in a smooth epithelial cell surface pattern. 
b IgG staining in a granular epithelial cell surface pattern
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Antibodies against DSG1 and/or DSG3 can be measured 
by the ELISA technique in approximately 90% of patients 
with pemphigus [6]. Antibody titers against DSG1 meas-
ured by ELISA correlate well with the disease activity of 
PV, whereas DSG3 antibody titers correlate with the disease 
course in only two thirds of the patients [136, 137]. In sev-
eral patients with PV, high levels of DSG3 antibodies remain 
measurable after achieving remission, and it is hypothesized 
that they might be non-pathogenic [138]. Immunoblot is 
not useful for the diagnosis of PV because anti-DSG1 and 
DSG3 autoantibodies are often directed against conforma-
tion epitopes, meaning that the denaturation process changes 
the epitopes’ composition, and therefore immunoblot will 
be negative [133].
The diagnosis of PNP is based on the detection of autoan-
tibodies against envoplakin and periplakin, or A2ML1. Radi-
oactive and nonradioactive immunoprecipitation is the most 
sensitive (95%) and specific (100%) method, but these tests 
are not widely available (Fig. 5c). Immunoblot can show 
reactivity against the 210-kDa envoplakin, 190-kDa peri-
plakin, 180-kDa BP180, 230-kDa BP230, 250 and 210-kDa 
desmoplakin I and II, and 500-KDa plectin (Fig. 5c). Immu-
noblot in combination with IIF on the rat bladder has shown 
to be an excellent alternative for immunoprecipitation, 
with very high sensitivity and specificity. This alternative 
provides a valuable, relative easy method to perform PNP 
diagnostic in most laboratories [93].
6  Conclusions
Clinicians should be aware that oral lesions in AIBD may 
look similar, and might be the only manifestation of disease. 
A quick and proper diagnosis is necessary for adequate treat-
ment, which may take place in a multi-disciplinary setting. 
Direct immunofluorescence on a biopsy from skin or mucosa 
combined with IIF and additional serological tests are the 
cornerstones for the diagnosis of AIBD. By following the 
described diagnostic algorithm, clinicians should be able to 
recognize and accurately diagnose AIBD affecting the oral 
mucosa.
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